Qilian International Corp (QLI) Price-to-Projected Revenue Ratio
The specifics of Qilian International (QLI) asset management in Asia necessitate increased compliance transparency, which is clearly demonstrated by the forward P/S ratio. Currently, the relevant mark stands at 4.20. Strict government licensing of Chinese raw materials stabilizes the situation by creating barriers for competitors, although the depreciation of production capacities limits margin growth and constrains the business's operational efficiency.
Qilian International Holding - analytical breakdowns and key metrics (QLI)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- business debt structure and liquidity details:
Debt to Equity Qilian International|QLI - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio Qilian International Holding|QLI - Aggregate Debt Obligations|Debts to Book Capitalization Qilian International Holding Group Limited|QLI - Long-Term Debt Volume|Company Short-Term Debt Qilian International|Quick Liquidity Indicator qlsyy.net
- financial results and valuation multiples details:
QLI - Profit After Payment of Taxes|Projected Future Earnings Qilian International|QLI - Market Cap to Earnings|Future Price to Earnings Qilian International|QLI - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Qilian International Holding Group Limited|QLI - Operating profit before amortization|Net earnings per share (EPS TTM) Qilian International|QLI - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months qlsyy.net|QLI - Net earnings per one share growth for the current year|Earnings growth forecast for next year Qilian International
- sales volume and revenue indicators:
Summary company analysis:Qilian International Corp QLI
The forward P/S reflects the market value of Qilian International (QLI) relative to its expected sales volume, allowing for an assessment of the premium or discount to projected revenue. By analyzing changes in the forward P/S, an investor determines the asset's margin of safety, which is critical for Qilian International (QLI) amid capacity modernization and expansion within the Asian organic fertilizer and traditional medicine segments.
Analysis of competing companies
Forward P/S Multiple HLN (Haleon PLC)|Forward P/S Multiple Kenvue Corp KVUE|Verona Pharma PLC - Forward P/S Multiple|Market Cap to Future Revenue Ratio jyongbio.com|LGND: Forward P/S Multiple|Market Cap to Projected Revenue AMRX|Price-to-Projected Revenue Ratio Perrigo Company|Market Cap to Future Revenue Ratio Alvotech ALVO|Forward P/S Multiple LQDA|GLPG: Future Price to Revenue|Forward P/S Multiple ANIP (ANI Pharmaceuticals, Inc.)|Market Cap to Expected Sales Ratio MannKind Corp (MNKD)|AMPH: Forward Price-to-Revenue Multiple|Forward Price to Sales PCRX (Pacira)|ARS Pharmaceuticals (SPRY) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TBPH|AQST (Aquestive Corp) - Forward P/S Multiple|Forward Price-to-Revenue Multiple scPharmaceuticals Inc. (SCPH)|Forward Price-to-Revenue Multiple TECX (Tectonic Therapeutic, Inc.)|TNXP (Tonix Pharmaceuticals Holding) - Forward Price to Sales|Price-to-Projected Revenue Ratio SXT Pharmaceuticals SXTC|Forward Price to Sales EPRX|BHST - Price-to-Projected Revenue Ratio|eXoZymes (EXOZ) - Forward Price-to-Revenue Multiple|ORMP: Forward P/S Multiple|ENTX: Price to Expected Revenue Ratio|HYFT (ipatherapeutics.com) - Forward P/S Multiple|Forward P/S Multiple ABVC BioPharma|Price-to-Projected Revenue Ratio Cumberland Pharmaceuticals Inc. (CPIX)|QNTM (Quantum BioPharma Ltd.) - Forward Price to Sales|Forward P/S Multiple FGEN (fibrogen.com)|Telomir Pharmaceuticals (TELO) - Market Cap to Future Revenue Ratio|RANI - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Synergy CHC SNYR|RLYB: Forward P/S Multiple|Market Cap to Future Revenue Ratio Lexaria (LEXX)|Price-to-Projected Revenue Ratio Pulmatrix|Market Cap to Projected Revenue PTHL (ftzy.com.cn)|Forward P/S Multiple APM|Lyra Therapeutics, Inc. - Market Cap to Projected Revenue|Forward P/S Multiple IBO (impactbiomedinc.com)|TNFA: Market Cap to Projected Revenue|YCBD - Price-to-Projected Revenue Ratio|PRFX - Forward P/S Multiple|CYTO (altamiratherapeutics.com) - Forward Price-to-Revenue Multiple|LIPO - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple OPTN|Pieris Pharmaceuticals Inc (PIRS) - Market Cap to Expected Sales Ratio|Forward P/S Multiple PROC|PTPI: Future Price to Revenue|ACELYRIN, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple tffpharma.com TFFP
